CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
Pharmaceutical Technology
MARCH 21, 2023
A few weeks later, the EC extended the approval label of AstraZeneca’s Forxiga (dapagliflozin) to include the treatment of symptomatic hearth failure. The vaccine ACI-24.060 elicited an anti-Abeta antibody response in the first patient cohort after six weeks, as per the results.
59 
Let's personalize your content